Related Experiment Video
Updated: May 13, 2026

Glaucoma-inducing Procedure in an In Vivo Rat Model and Whole-mount Retina Preparation
Published on: March 12, 2016
[Glaucoma: pharmacological implications]
C Rieger-Reyes1, F J Rubio-Galán
1Unidad Docente Medicina de Familia y Comunitaria Sector II, Zaragoza, España. cris.rieger.reyes@gmail.com
Abstract:
Glaucoma is the first cause of irreversible blindness worldwide. Its prevalence in our country is 2%; half of patients remain undiagnosed. Certain drugs can trigger and/or exacerbate glaucoma; hence the importance of having knowledge of these drugs by Primary Care physician. In addition, the drugs used in the treatment of glaucoma, even topically, can have systemic side effects that should be also know to the Primary Care physician. An adequate knowledge of all the drug groups and the prescribing of the appropriate drug in patients with risk factors and underlying pathology, will enable the Primary Care physician to optimise the risk/benefit ratio in the therapeutic management of these patients. An update is presented on this ophthalmological disease, with special attention to its implications for pharmacological treatments.
Related Concept Videos
Open Angle Glaucoma: Treatment
Drugs such as carbonic anhydrase inhibitors, α2- and...
Glaucoma: Overview
Angle Closure Glaucoma: Treatment
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Absorption
Direct-Acting Cholinergic Agonists: Pharmacological Actions
Ophthalmic Drug Delivery Systems

